PARKINSON S AWARENESS & SUPPORT ASSOCIATION of the TRI-STATE (PASATS)
|
|
- Linette Cunningham
- 5 years ago
- Views:
Transcription
1 PARKINSON S AWARENESS & SUPPORT ASSOCIATION of the TRI-STATE (PASATS) The Red Tulips by Nikki Pritchett Resource Guide
2 NATIONAL SUPPORT National Parkinson s Disease Organizations Michael J Fox Foundation Parkinson Foundation PD Help Line Davis Phinney Foundation
3 Local Support Groups PASATS- Parkinson s Awareness and Support Association of the Tri-State Meets monthly, check website for details Care Partners Support Group- Meets bi-monthly, check website for details LOCAL SUPPORT 3
4 Parkinson s was originally described in 1817 by James Parkinson in his Essay on the Shaking Palsy. What researchers have come to understand is that Parkinson s Disease is a neurological disorder in which there is a gradual loss of brain cells that make and store dopamine. Dopamine is a chemical in the brain, known as a neurotransmitter, which sends messages that control movement. As PD progresses, more dopamine neurons in the brain are lost. The primary symptoms of PD are movement related, and include: resting tremor, rigidity and slowness of movement. However, many patients also experience non-movement related symptoms such as cognitive impairment, mood changes, constipation and blood pressure problems. PARKINSON S DISEASE 101 The causes of PD remain unknown, although researchers believe the disease may be brought on by a combination of environmental and genetic factors. Available treatments help to reduce some of the symptoms but there is currently no treatment that can slow or stop the disease from progressing over time. Much research is ongoing to identify strategies for improving treatment of PD in the future. Source: Partners in Parkinson s- Parkinson s Disease Guide INTRODUCTION 4
5 Parkinson s patients experience a wide range of symptoms and it varies for each person. There is no diagnostic test that determines whether a person has developed PD, rather a thorough examination of one s medical history and a physical examination helps to detect symptoms synonymous with PD. Movement/Motor-Related Symptoms Bradykinesia slowing down and loss of spontaneous and voluntary movement Rigidity unusual stiffness in a limb or other body part Resting Tremor an uncontrollable movement that affects a limb when it is at rest and usually stops for the duration of a voluntary movement Postural Instability problems with standing or walking, or impaired balance and coordination, which can lead to falls Dystonia involuntary movement with a muscle contraction, such as a cramp SYMPTOMS OF PD Reduced facial expression mask-like face due to bradykinesia Speech and swallowing problems Other Treatment-Related Symptoms Dyskinesia involuntary twisting/turning, jerky movements that can result from long-term use of medications that treat PD Impulse Control inability to resist an impulse that is harmful to self or others that can result from use of medications that treat PD 5
6 Non-Motor Related Symptoms Cognitive Impairment: decline in ability to multi-task and/or concentrate; potential decline in intellectual functioning and onset of psychosis Mood changes: can include depression, apathy or anxiety Sleep disorders: REM sleep behavior disorder, for example, where individuals act out their dreams Hyposmia: loss of sense of smell Fatigue Constipation Bladder problems: a sudden need to urinate or incontinence Orthostatic Hypotension: low blood pressure upon standing Central pain: other than pain caused by posture problems or dystonia 6
7 MEDICATION MANAGEMENT Because many Parkinson s symptoms are due to the lack of dopamine the brain chemical that plays an important role in behavior, coordination and mobility patients are commonly prescribed dopamine medications. Dopamine drug side effects include: nausea, drowsiness, low blood pressure, hallucinations and dyskinesia writhing movements. Choosing the right medication is directly related to the patient s ability to handle its side effects. Balancing the ideal medication program and schedule can be easy for some and very challenging for others. Medication is most effective when taken on a regular schedule and combined with exercise, good nutrition and rest. 7
8 COMMON PD MEDS This list was compiled using information from The Parkinson s Disease Foundation s Parkinson s Disease Q & A, (Sixth Edition, 2012) and its website For more information about medicines, contact your physician. Class Medication (common name) Function Side Effects Levodopa Carbidopa/Levodopa(Sinemet ) Carbidopa/Levodopa controlled release (Sinemet CR ) Carbidopa/Levodpa orally disintegrating tablet (Parcopa ) Carbidopa/Levodopa/Entacapone (Stalevo ) Converts into dopamine to manage major symptoms Low blood pressure, nausea and vomiting, dyskinesia, dry mouth, dizziness Dopamine Agonists Apomorphine (Apokyn ) Bromocriptine (Parlodel ) Pramipexole (Mirapex ) Pramipexole dihydrochloride extendedrelease (Mirapex ER ) Ropinirole (Requip ) Ropinirole extended-release tablets (Requip XL) Rotigotine transdermal system (Neupro ) Stimulates brain as if given dopamine; compliments levodopa & helps deter symptoms beween levodopa doses. Does not cause dyskinesias, but can lead to nausea, hallucinations, sleepiness & lightheadedness COMT (Catechol-O-Methyl Transferase) Inhibitors Entacapone (Comtan ) Tolcapone (Tasmar ) Helps extend effect of levodopa Abdominal pain, back pain, constipation, nausea, diarrhea, blood in urine, liver failure 8
9 COMMON PD MEDS As the pharmaceutical industry continues to evolve, PD patients have many options in which to purchase meds. Below is list of PSC supporters who are in the pharmaceutical industry. Class Medication (common name) Function Side Effects MAO-B (Monoamine oxidase) Inhibitors Rasagiline (Azilect ) Selegiline or deprenyl (Eldepryl ) Seleginilie HCI orally disintegrating tablet (Zelapar ) Blocks enzyme in the brain that breaks down levodopa. Dizziness, nausea, pain, head-ache, insomnia, rhinitis, dyskinesia, back pain, stomatitis, dyspepsia Anticholinergics Benztropine mesylate (Cogentin ) Procyclidine (not in US) Trihexyphenidyl (Artane ) Helps with tremors and dystonia Blurred vision, dry mouth, constipation and urinary retention 9
10 EXERCISE Ace CARE University of Evansville Physical Therapy Program physicaltherapy/acecare.cfm Delay the Disease Classes offered at several Evansville locations (812) Find the locations at Parkinson s Exercise Class HealthSouth Deaconess Rehab Hospital 4100 Covert Ave Evansville IN Healthsouth-Parkinson-s-Exercise-Class/Parkinson-s-Disease-Exercise-Class-(13) Rock Steady Boxing Evansville IN YMCA Downtown 222 NW 6th St Evansville, IN For other locations 10
11 Deaconess Pelvic Health & Wellness Center 4199 Gateway Blvd. Newburgh, IN Services/Pelvic-Health-Wellness-Center HealthSouth Deaconess Rehabilitation Hospital 4100 Covert Ave. Evansville, IN rehabilitation-programs LSVT Big & LOUD provider Progressive Health Orthopedic Dr. Newburgh, IN LSVT Big provider ProRehab (east side office) 415 Crosslake Drive Suite B Evansville, IN Outpatient & In-Home Services available LSVT Big provider Rehab for Life 1449 Kimber Lane, Suite 103A Evansville, IN Transportation available St. Vincent Rehabilitation Institute Outpatient Rehab - Washington Square Mall 1144 Washington Square Evansville, IN LSVT Big & LOUD provider NOTE: Listing of all LSVT Big & LOUD providers go to AND SPEECH THERAPY PHYSICAL, OCCUPATIONAL, 11
12 Locally Owned Parmacies Paul s Pharmacy East Location 1225 Washington Square Evansville, IN Pharmaceutical Patient Assistant Program Needy Meds Help Line Partnership for Prescription Assistance Patient Access Network Foundation (PANF) RX Assistance Select Care Benefits Network
13 Restorative Therapy Deep Brain Stimulation (DBS) Educational Classes St. Vincent Evansville Gift Room 3700 Washington Ave Evansville, IN Aaron Stults Motion Studio 3211 Grant Line Rd. #13 (47150) Durable Medical Equipment Advanced Medical Equipment Services 1741 Oak Hill Road Evansville IN Deaconess Home Medical Equipment Easter Seals Rehabilitation Center Provides assistive technology services and driving assessments U-Step walkers HLS Health + Wellness 1330 N. Green River Road Evansville IN St. Vincent Evansville Medical Equipment
14 ORGANIZATIONS AND SERVICES CHARITABLE ORGANIZATIONS Melvin Weinstein s Parkinson Foundation Assist PD patients with devices and medications mwpfassistance@verizon.net HOME HEALTH SERVICES Deaconess Hospital Hospice/Home-Health-Care Home Instead Senior Care Horizons Home Care Senior Helpers Specialty Home Health Care St. Vincent Evansville Green Valley Care Center private nursing home accepts Medicare & Medicaid 3118 Green Valley Rd, New Albany (47150) (812)
15 PALLIATIVE CARE SERVICE Deaconess Hospital Palliative-Care VETERAN SERVICES Evansville Health Care Center 6211 E. Waterford Blvd. Evansville, IN St. Vincent Hospital AseraCare Hospice 1401 Professional Blvd. #201 Evansville, IN HOSPITALS & DOCTORS Southern Indiana Rehab Hospital Jen Robinson, PT 3104 Blackiston Blvd. New Albany, IN Wellstone Regional Hospital 2700 Vissing Park Rd, Jeffersonville, IN LEGAL & FINANCIAL Schad & Schad Trial Lawyers 223 E Spring St (47150)
16 TRANSPORTATION & MOBILITY METS -Metropolitan Evansville Transit System (City Bus) METS MOBILITY For those 65 years or older or those with a documented disability that limits the use of the METS regular route system Superior Van & Mobility Interstate Drive Evansville IN DISABLED PARKING PERMITS City of New Albany (IN) HANDICAPPED PARKING PERMITS INDIANA Motor Vehicle & Boats Disabled Parking Obtain form from Clerk s office (available online) Form needs physician s signature and must be notarized Small fee 16
17 RAMP SERVICES Lifespan Resources (New Albany IN) Connect2Help United Way of Central Indiana s Resource Guide Phone: 211 Senior Resource Guide of Southern Indiana Available in English & Spanish SWIRCA & More Non- profit organization serving seniors, people with disabilities, and their caregivers. 16 W. Virginia St. Evansville, IN SOCIAL SECURITY/MEDICARE/ MEDICAID 3700 Blackiston Blvd (47150) (800) PERSONAL TRAINERS (with specialized training for PD) Harley Wilson harleywilson@bobsgym.com Bob s Gym Newburgh Parkinson s Fitness Certified Instructor Delay the Disease 8120 High Pointe Dr Newburgh, IN Nikki Pritchett, ACSM Certified, Personal Trainer Studio on the Blvd In-home personal training focuses on strength, balance and flexibility Certified Rock Steady Boxing Coach studioontheblvd@gmail.com ORGANIZATIONS OTHER 17
18 ADULT PROTECTIVE SERVICES & ADVOCACY Clark County Adult Protective 501 E Court Ave #215 Jeffersonville, IN Criminal Division (812) Partners in Parkinson s WEB-BASED BUSINESSES Free Rider USA In-Step Mobility Products, Inc. Walking Aids Designed Specifically for Neurological Conditions LiftWare (weekdays 6am 5pm PACIFIC TIME) Luggie Scooters Speak Up for Parkinson s mobile app Guardian Medical Monitoring Phone:
19 CREATING A PERSONAL SUPPORT TEAM No matter where you are in your treatment, it is important to have a Support Team. The following is a recommended list of a variety of individuals who can assist: Movement Disorder Specialist A neurologist who is trained specifically to treat movement disorders, such as Parkinson s disease. Movement disorder specialists must complete their residency training in neurology and then complete additional training (a fellowship) in movement disorders Physician/Neurologist Responsible for directing your care. They are seen as the lead in your treatment program and should be consulted if you have any questions or concerns Nurse/Caregiver Helps with specific or daily personal care and needs Physical Therapist Uses specially designed exercises and equipment to help patients regain or improve their physical abilities Occupational Therapist Helps regain independence of daily activities Speech Therapist Works to improve speaking, swallowing, reading and writing Dietitian Social Worker /Case Manager Pharmacist Chaplain/Spiritual Leader Psychologist/Neuropsychologist Legal and Financial Planners Other Tips: Find a Support Group Access Community Health Networks Join a Clinical Trial Attend Education Conferences 19
20 LIVE WELL WITH PARKINSON S DISEASE Providing a healthier and improved quality of life while expanding our legacy of service Explore our services Access to care Education Advocacy Social assistance Support groups Exercise Classes (502) PARKINSONCENTER.ORG info@parkinsoncenter.org 315 Townepark Circle, Suite 100 Louisville, KY 40243
Optimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationUnderstanding Parkinson s Disease Important information for you and your loved ones
Patient Education Understanding Parkinson s Disease Important information for you and your loved ones This handout explains the signs, symptoms, and possible treatments of Parkinson s disease. Parkinson
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationThe symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:
1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing
More informationParkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust
n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationKey Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationMedication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationCardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.
Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor
More informationHeadway Victoria Epilepsy and Parkinson s Centre
Headway Victoria Epilepsy and Parkinson s Centre Parkinson s Overview and Medication Shannon Oatway Community Education/ Awareness Coordinator What is Parkinson s Disease? The basics It is a chronic and
More informationObjectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.
Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center
More informationWELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW
WELCOME Parkinson s 101 for the Newly Diagnosed Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW Parkinson s Disease 101 Presenter for Today Cari Friedman, LCSW Patient and Family Service
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationParkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015
Parkinson s Disease Update Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015 Parkinson s Disease Progressive, chronic, neurodegenerative disease Slow,
More informationDrugs for Parkinson s Disease
This Clinical Resource gives subscribers additional insight related to the Recommendations published in July 2017 ~ Resource #330705 Drugs for Parkinson s Disease Parkinson s disease is characterized by
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Xadago GENERIC NAME Safinamide MANUFACTURER Newron Pharmaceuticals SpA holds license; granted approval. US WorldMeds, LLC exclusive licensee and distributor in the U.S. DATE OF APPROVAL March
More informationChapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis
Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral
More informationFOR PARKINSON S DISEASE XADAGO NEXT?
FOR PARKINSON S DISEASE XADAGO can increase your daily on time without troublesome dyskinesia 1 Please see the complete Important Safety Information on pages 12-13 and the accompanying full Prescribing
More informationThe Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates
The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates Editor: Marsha K. Millonig, MBA, RPh President/CEO Catalyst Enterprises,
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationWhat is Parkinson s Disease?
2018 Update in Parkinson s Disease: Treatments and Future Plans Arita McCoy, MSN, CRNP Johns Hopkins Parkinson s Disease and Movement Disorder Center A National Parkinson Foundation Center of Excellence
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More information9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations
Parkinson s Disease Update Clinical and Operational Considerations Dana Saffel, PharmD, BCGP, CPh, FASCP President, CEO PharmaCare Strategies, Inc. September 2018 Objectives Describe epidemiology and pathophysiology
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationNon-Motor Symptoms of Parkinson s Disease
Non-Motor Symptoms of Parkinson s Disease Samantha Holden, MD University of Colorado Movement Disorders MOTOR SYMPTOMS Rigidity Bradykinesia Tremor Gait Imbalance NON-MOTOR SYMPTOMS Dementia Urinary frequency
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationPARKINSON SUPPORT CENTER
PARKINSON SUPPORT CENTER Resource Guide (502) 254-3388 PARKINSONCENTER.ORG info@parkinsoncenter.org 315 Townepark Circle, Suite 100 Louisville, KY 40243 NATIONAL RESOURCES National Resources American Parkinson
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationWhat is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease
FPIN's Clinical Inquiries Treatment of Early Parkinson's Disease Clinical Question What is the best medical therapy for early Parkinson's disease? Evidence-Based Answer Treatment of early Parkinson's disease
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More informationNMG-NEUROLOGY Dr. Bega, Dr. Malkani, Dr. Melen, Dr. Opal, Dr. Simuni, and Dr. Zadikoff MEDICAL BACKGROUND AND INFORMATION FORM
Page 1 of 5 Patient Name: Date of Birth: MRN: Encounter #: NMG-NEUROLOGY Dr. Bega, Dr. Malkani, Dr. Melen, Dr. Opal, Dr. Simuni, and Dr. Zadikoff MEDICAL BACKGROUND AND INFORMATION FORM Thank you for taking
More informationScottish Medicines Consortium
Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium
More informationAn Overview of Parkinson s Medication used in Multiple System Atrophy
Introduction The cause of Parkinson s symptoms The types of Parkinson s drugs used in MSA Finding the best medication Additional medication Drugs to avoid Further information An Overview of Parkinson s
More informationAn Overview of Parkinson s Medication used in Multiple System Atrophy
Introduction Cause of Parkinson s symptoms Parkinson s drug use in MSA Finding the best medication Other medication - Interaction Drugs to avoid Further information An Overview of Parkinson s Medication
More informationSection 1: What is Parkinson s? Parkinson's Disease Webinar 4/27/2012. April 27th, :00-1:00 PM EST
4/27/2012 Parkinson's Disease Webinar April 27th, 2012 12:00-1:00 PM EST Presenter: Jon Collins, Manager, Programs and Events, Parkinson Society Central & Northern Ontario Section 1: What is Parkinson
More informationParkinson s Disease Foundation. PD ExpertBriefing: Managing the Motor Symptoms in PD
Parkinson s Disease Foundation PD ExpertBriefing: Managing the Motor Symptoms in PD Led By: Sotirios A. Parashos, M.D. Minneapolis Clinic of Neurology and Struthers Parkinson's Center This session was
More informationAppendix 2: Admissions checklists for people with Parkinson s
Appendix 2: Admissions checklists for people with Parkinson s This document is intended to form the basis of a locally developed tool and so it has been built to be amended with relevant local information,
More information475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)
475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive
More informationIssues for Patient Discussion
onmotor complications radykinesia Screening Tools asked PD micrographia eurodegeneration Designed for Use by Family Practitioners remor on-off opamine agonists tiffness depression ostural instability wearing
More informationParkinson s Disease. Medications
Parkinson s Disease Medications By David Houghton, MD, MPH, Howard Hurtig, MD, and Sharon Metz, RN, MPH, with guest authors Monique Giroux, MD, Giselle Petzinger, MD, Beth Fisher, PT, PhD, Lauren Hawthorne,
More informationEXPLORING OPPORTUNITIES TO PARTNER TOWARD CURES FOR PD. Chicago Clinical Research Fair June 11, 2016
EXPLORING OPPORTUNITIES TO PARTNER TOWARD CURES FOR PD Chicago Clinical Research Fair June 11, 2016 HOW DO WE LEARN MORE ABOUT PARKINSON S DISEASE? Patient-reported data Diagnosis and clinical symptoms
More informationParkinson s Disease and Treatment Options for the Younger Adult
Parkinson s Disease and Treatment Options for the Younger Adult David E. Riley, M.D. Chair, Medical Education InMotion April 22, 2016 Case Presentation - 1 A 57-year-old woman had Tremor of her right hand
More informationParkinson s Disease and Treatment Options for the Younger Adult
The Way CME Should Be Parkinson s Disease and Treatment Options for the Younger Adult David E. Riley, M.D. Chair, Medical Education InMotion April 22, 2016 Case Presentation - 1 A 57-year-old woman had
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationThe PD You Don t See: Cognitive and Non-motor Symptoms
The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver Goals
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationUNDERSTANDING PARKINSON S AND THE POWER OF INTENT. Samantha Elandary, MA, CCC-SLP Founder & Chief Executive Officer Parkinson Voice Project
UNDERSTANDING PARKINSON S AND THE POWER OF INTENT Samantha Elandary, MA, CCC-SLP Founder & Chief Executive Officer Parkinson Voice Project What is Parkinson s? TOOLS FOR MANAGING PARKINSON S! Medications!
More informationParkinson's Disease and how you can make a difference with medication
Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationClinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: 05.16.17 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationDrug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)
Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl
More informationPD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.
PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and
More informationDate of Referral: Enhanced Primary Care Pathway: Parkinson s Disease
Specialist LINK Linking Physicians CALGARY AND AREA Patient Name: Date of Birth: Calgary RHRN: PHN / ULI: Date of Referral: Referring MD: Fax: Today s Date: CONFIRMATION: TRIAGE CATEGORY: REFERRAL STATUS:
More informationParkinson's Disease KP Update
Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have
More informationPARKINSON S SYMPTOM TRACKER
PARKINSON S SYMPTOM You can help your doctor make good treatment decisions by tracking your symptoms. A well-kept Symptom Tracker provides a clear picture of when you are taking your medications, when
More informationACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD
More informationAhead of the curve: Parkinson s Disease 101. Luisa Solis-Cohen, MD Movement Disorders Specialist Colorado Neurodiagnostics Littleton, CO
Ahead of the curve: Parkinson s Disease 101 Luisa Solis-Cohen, MD Movement Disorders Specialist Colorado Neurodiagnostics Littleton, CO Our goals for discussion... 1. Recognize the motor symptoms of Parkinson
More informationThe Fresco Institute for Parkinson's and Movement Disorders
The Fresco Institute for Parkinson's and Movement Disorders Follow Up Patient Questionnaire Name: Date: Accompanied by: Do you smoke? CURRENT PAST NEVER Which neurological symptom bothers you most right
More information8/28/2017. Behind the Scenes of Parkinson s Disease
BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic
More information2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).
Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,
More informationEnhanced Primary Care Pathway: Parkinson s Disease
Enhanced Primary Care Pathway: Parkinson s Disease 1. Focused summary of PD relevant to primary care Parkinson s Disease (PD) and Essential tremor (ET) are two of the most common movement disorders encountered
More informationMargo J Nell Dept Pharmacology
Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce
More informationAdvances in Parkinson s Disease Treatment. Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL
Advances in Parkinson s Disease Treatment Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL Uitti.ryan@mayo.edu Ryan J. Uitti, MD Disclosure receives research support from NIH/NINDS,
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationE L S. Parkinson s disease Challenges, Progress and Hope Course # Contact Hours. Just Learning! Material Valid Through December 2019
Parkinson s disease Challenges, Progress and Hope Course # 226 5 Contact Hours Authors: Ellen Steinbart, RN, MA Meredith Patterson, RN, BSN, CRRN Material Valid Through December 2019 Copyright 2016 J.L.
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationParkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder
Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age
More informationTHE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE
THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE J O N AT H A N S Q U I R E S, M D, F R C P C C L I N I C A L I N S T R U C T O R, UBC F AC U L T Y O F M E D I C I N E P AC I F I C P AR K I N S
More information(safinamide) tablets
FOR PARKINSON S DISEASE (PD) GET TO KNOW XADAGO can increase your daily on time without troublesome dyskinesia (uncontrolled movement) Please see the complete on pages 14-15 and For Parkinson s disease
More informationParkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center
Parkinsons Disease update Sindhu R Srivatsal MD MPH Virginia Mason Medical Center PARKINSONISM Vs PARKINSON S Parkinsonism Bradykinesia: slowness of movements (essential feature) PLUS one of Tremor: resting
More informationPARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada
PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationLet s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016
Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 What is Parkinson s? Parkinson's is a progressive neurological condition. People
More informationMANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW
MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW Author: Gordon W Duncan Status: Approved Authorised by: Clinical Policy Group Version: 1.0 Review date:
More informationParkinson s Disease An Open Doors Perspective
Parkinson s Disease An Open Doors Perspective MFP Transition Center Nurse Laura Bingell RN Open Doors is a Money Follows the Person program of New York Association on Independent Living under contract
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Drugs for Neurodegenerative Diseases 2 Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 DRUGS USED IN PARKINSON S DISEASE/ B. Selegiline and rasagiline Selegiline, also called
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More information